atients with hepatitis C virus with renal dysfunction represent a difficult to treat population. Pegylated interferon monotherapy has been the standard treatment in such patients. However, sustained virologic response (SVR) rates were quite low and discontinuation rates were relatively high in these populations. Direct-acting antivirals are effective and safe in patients with hepatitis C virus. Sofosbuvir, which is one of the key drugs, is metabolized in kidney.
P
atients with hepatitis C virus with renal dysfunction represent a difficult to treat population. Pegylated interferon monotherapy has been the standard treatment in such patients. However, sustained virologic response (SVR) rates were quite low and discontinuation rates were relatively high in these populations. 1 Direct-acting antivirals are effective and safe in patients with hepatitis C virus. Sofosbuvir, which is one of the key drugs, is metabolized in kidney. 2 Therefore, sofosbuvir is not recommended for use in patients with estimated glomerular filtration rate (eGFR) of <30 mL/min, 3 and not approved for use in Japan for these patients. In contrast, daclatasvir (DCV) and asunaprevir (ASV) are metabolized in liver. It has been reported that the blood concentration of these drugs did not differ between patients with and without severe renal dysfunction. 4, 5 In this study, we investigated the efficacy and safety of treatment with the combination of DCVþASV in patients with renal dysfunction infected with hepatitis C virus genotype 1b.
Methods
We conducted a multicenter study using the DCVþASV regimen used in clinical practice at Nagoya University Hospital and 50 affiliated hospitals. Among 924 patients in total, 897 patients were investigated for efficacy and safety after excluding the patients whose baseline renal functions were missing. A total of 110 patients had eGFR of <50 mL/min, and 43 patients had eGFR of <30 mL/min. This study was approved by the ethical committee of Nagoya University (approval number, 2014-0211) and conformed to the ethical guidelines of the 1975 Declaration of Helsinki.
Results
SVR12 rate was 89.3% (592 of 663) in patients with eGFR of 50 mL/min, 93.0% (53 of 57) in patients with eGFR of 30-49 mL/min, and 97.0% (32 to 33) in patients with eGFR of <30 mL/min (P ¼ NS). Early viral response at 2 weeks after the start of treatment was significantly higher in patients with eGFR of <30 mL/min (30 of 34; 88.2%) than in patients with eGFR of 30 mL/min (274 of 459; 59.7%; P ¼ .001).
There were no significant differences in discontinuation rates between patients with and without renal dysfunction: eGFR of 50 mL/min, 8.5% (67 of 787); eGFR of 30-49 mL/min, 11.9% (8 of 67); eGFR of <30 mL/min, 4.7% (2 of 43) (P ¼ NS). A total of 6.1% (48 of 787) of patients experienced grade 3 or higher liver injury (defined as alanine aminotransferase 5 times the upper limit of normal) ( Figure 1A ) in patients with eGFR of 50 mL/min. In contrast, 3.0% (2 of 67) ( Figure 1B ) of patients with eGFR of 30-49 mL/min and none of the patients with eGFR <30 mL/min experienced liver injury (0 of 43) ( Figure 1C ). Only 1.8% (2 of 110) ( Figure 1D ) of patients with eGFR of <50 mL/min developed liver injury, compared with 6.1% (48 of 787) ( Figure 1A ) of patients with eGFR of 50 mL/min (P < .001).
Discussion
There have been 2 recent reports showing the effect of DCVþASV treatment in patients on hemodialysis. 6, 7 In 1 of those studies, Toyoda et al 7 reported that patients receiving hemodialysis showed an earlier viral response and almost the same SVR rates as patients without renal dysfunction. Our results confirmed these findings and we also showed that SVR was similar in all patients regardless of the severity of renal dysfunction. In regards to safety, the incidence of liver injury was significantly lower in patients with versus those without renal dysfunction. Kawakami et al 8 showed that the plasma concentration of ASV, which is the main cause of liver injury, is significantly lower in patients with renal dysfunction compared with those with normal renal function; this may provide 1 explanation of the results of the present study. However, other previous studies in patients with hemodialysis did not report remarkable difference in liver injury compared with those without. 6, 7 This discrepancy might be explained by the number of patients studied or by the inclusion criteria of the analysis. However, this issue should be resolved in future studies.
In conclusion, treatment with the combination of DCVþASV has at least the same effectiveness and safety in patients with renal dysfunction as in those without renal dysfunction. In terms of safety concerns, fewer patients with renal dysfunction developed liver injury than those without renal dysfunction. 
